X-Cor Therapeutics Inc.
- UEI
- C8ALEDEUU658
- CAGE
- 86X62
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- xcortherapeutics.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 59 Miscellaneous Retail
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase i: respiratory dialysis for extracorporeal carbon dioxide treatment of copd -the broader impact of this small… | National Science Foundation | $274,274 | |
| Development of a CO2-bicarbonate combined membrane capture system for accessible treatment of acute respiratory failure. | National Heart Lung and Blood Institute | $1,172,470 |
About X-Cor Therapeutics Inc.
X-Cor Therapeutics Inc. is a corporate entity registered in Washington, DC, classified as a minority-owned, small disadvantaged business that specializes in medical technology innovation. The company is a for-profit organization and manufacturer of goods, with a specific focus on developing advanced medical devices for respiratory care. Registered in SAM.gov since October 2018, X-Cor Therapeutics demonstrates expertise in developing sophisticated medical technologies targeting respiratory health challenges, particularly for patients with chronic obstructive pulmonary disease (COPD).
The company has received federal grant awards from prominent agencies like the National Science Foundation (NSF) and the National Heart Lung and Blood Institute, focusing on developing innovative extracorporeal carbon dioxide removal systems for respiratory treatment. Their most recent NSF Technology, Innovation, and Partnerships grant awarded in August 2024 involves developing a novel respiratory dialysis system to remove excess CO2 from COPD patients' blood, with the potential to reduce mechanical ventilation and associated complications. In collaboration with Johns Hopkins University, X-Cor Therapeutics has been advancing prototype development for a CO2-bicarbonate combined membrane capture system aimed at treating acute respiratory failure. Their research involves complex medical device development, including designing specialized dialysate systems, implementing dialysate recirculation loops, and creating technologies that could potentially reduce hospitalizations and treatment costs for respiratory patients. The collaborative nature of their work, involving academic partnerships and rigorous prototype validation, underscores their commitment to advancing medical technology through targeted research and innovation.
Quick answers
What is X-Cor Therapeutics Inc.'s UEI?
X-Cor Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is C8ALEDEUU658.
What is X-Cor Therapeutics Inc.'s CAGE code?
X-Cor Therapeutics Inc.'s CAGE code is 86X62.
What is X-Cor Therapeutics Inc.'s primary NAICS code?
X-Cor Therapeutics Inc.'s primary NAICS code is 339112 (Surgical and Medical Instrument Manufacturing).
Is X-Cor Therapeutics Inc. registered in SAM.gov?
X-Cor Therapeutics Inc.'s SAM.gov registration expired on July 29, 2026.
What is X-Cor Therapeutics Inc.'s most recent federal award?
X-Cor Therapeutics Inc.'s most recent federal grant award is Sbir phase i: respiratory dialysis for extracorporeal carbon dioxide treatment of copd -the broader impact of this small… (2415446), from National Science Foundation, on August 15, 2024.
On GovTribe
See X-Cor Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors